DDInter297 DDInter1376
Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Carbinoxamine {u} (Compound) resembles {v} (Compound) Bisacodyl
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Carbinoxamine {u} (Compound) binds {v} (Gene) CYP2C9
Carbinoxamine {u} (Compound) upregulates {v} (Gene) CDK6
Carbinoxamine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H1 Receptor Antagonists
Carbinoxamine {u} (Compound) downregulates {v} (Gene) CTNND1
Carbinoxamine {u} (Compound) causes {v} (Side Effect) Dizziness
Carbinoxamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aclidinium
Carbinoxamine {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Carbinoxamine (Compound) resembles Bisacodyl (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Carbinoxamine (Compound) binds CYP2C9 (Gene)
Carbinoxamine (Compound) upregulates CDK6 (Gene)
Carbinoxamine (Compound) is included by Histamine H1 Receptor Antagonists (Pharmacologic Class)
Carbinoxamine (Compound) downregulates CTNND1 (Gene)
Carbinoxamine (Compound) causes Dizziness (Side Effect)
Carbinoxamine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Carbinoxamine may lead to a major life threatening interaction when taken with Dextropropoxyphene